-
2024-517568-48-00
5
2025-07-21
Delayed Graft Function after Kidney Transplantation
-
2024-516162-11-00
5
2025-07-14
Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
-
2024-518771-66-00
9
2025-07-01
Hepatoblastoma, Rhabdomyosarcoma
-
2024-515646-16-00
4
2025-06-24
Recurrent, persistent, metastatic or locally advanced vulvar cancer
-
2023-509055-14-00
4
2025-06-17
acute myeloid leukemia (AML)
-
2023-510026-32-00
5
2025-06-11
Generalized Myasthenia Gravis
-
2023-509547-27-00
5
2025-05-22
Geographic Atrophy Secondary to Age-Related Macular Degeneration
-
2024-515526-89-00
4
2025-05-16
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2023-508507-20-00
5
2025-04-03
Locally advanced or metastatic conventional chondrosarcoma with an IDH
-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
-
2024-517771-21-00
11
2025-03-31
Acute kidney injury
-
2024-513550-30-00
5
2025-03-28
Newly diagnosed Glioblastoma
-
2024-516248-24-00
5
2025-03-28
Hereditary Angioedema
-
2022-500574-34-00
4
2025-03-21
Waldenström’s Macroglobulinemia
-
2024-515732-68-00
1
2025-03-07
Huntington’s disease
-
2022-500747-21-00
4
2025-02-27
Geographic Atrophy
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2023-509632-26-00
9
2025-02-11
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2023-505320-54-00
4
2025-01-30
Multiple System Atrophy
-
2023-510323-30-00
5
2025-01-24
First-line treatment of recurrent or metastatic PD-L1+ head and neck s